Researchers at the Montreal Heart Institute announced today results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39% in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths.
These patients also benefit from a reduction in the amount of atherosclerosis (thickened walls) in their vessels. The detailed results are published in the prestigious Journal Circulation Cardiovascular Genetics. This discovery may also pave the way for a new era in cardiovascular medicine, with personalized or precision drugs.
The team led by Drs Jean-Claude Tardif and Marie-Pierre Dubé performed the analysis of 5749 patients who received dalcetrapib or placebo and provided DNA in a clinical study. A strong association was discovered between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309). In patients with the genetic profile AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo. Supporting evidence was also obtained from a second study, which showed that patients with the favourable genetic profile also benefited from a reduction in the thickness of their carotid artery walls with dalcetrapib.
“These results will lead to a genetics-guided clinical study in patients with the appropriate genetic background to allow review by health regulatory agencies and to provide personalized therapy with dalcetrapib. It also offers great hope for precision treatments for patients with cardiovascular diseases and for curbing atherosclerosis, the first cause of mortality in the world” said lead investigator Jean-Claude Tardif MD, director of the Research Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.
The Latest on: Therapy for cardiovascular disease
via Google News
The Latest on: Therapy for cardiovascular disease
- Anticoagulants Market: Rise in Prevalence of Cardiovascular and Kidney Diseases to Drive Marketon October 9, 2020 at 1:53 am
Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K ...
- Study shows first known effective treatment for rare genetic disease alkaptonuriaon October 8, 2020 at 5:53 am
A new study published in The Lancet, led by a Liverpool based research collaboration, has identified the first effective treatment for a rare genetic condition known as alkaptonuria (AKU).
- General practice doctors failing to provide optimal treatment for heart disease patientson October 6, 2020 at 5:13 am
General practice management of patients with cardiovascular disease (CVD) is "suboptimal," with only 57% of patients with established CVD prescribed the guideline-recommended treatments, according ...
- Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1Bon October 5, 2020 at 9:55 am
Bristol Myers Squibb is bolstering its cardiovascular drug lineup with a $13.1 billion deal to acquire MyoKardia, a company whose experimental therapy for ...
- Study: Heart disease risk higher for people with spouses in ICUon October 5, 2020 at 8:06 am
Having a spouse in a hospital intensive care unit increases a person's risk for a heart attack or cardiac-related hospitalization, according to a study published in the journal Circulation.
- Bristol-Myers Agrees To Buy Heart Treatment Maker MyoKardia for $13.1 Billionon October 5, 2020 at 7:43 am
MydoKardia's experimental heart treatment, Mavacamten, was granted a "breakthrough therapy designation' from the U.S. Food & Drug Administration in July of this year.
- 2 Firms Drive $13.1B Heart Disease Treatment Developer Dealon October 5, 2020 at 5:40 am
Bristol Myers Squibb has agreed to pay $13.1 billion for MyoKardia, a clinical stage biopharmaceutical company focused on developing treatments for heart disease, the companies said Monday, in a deal ...
- Global Heart Valve Disease Treatment Marketon October 3, 2020 at 9:36 am
Data Bridge Market Research has recently added a concise research on the Global Heart Valve Disease Treatment Market to depict valuable insights related to significant market trends driving the ...
- FARXIGA Granted Breakthrough Therapy Designation in US for Chronic Kidney Diseaseon October 2, 2020 at 7:42 am
AstraZeneca’s FARXIGA® (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the US for patients with chronic kidney disease (CKD), with and without type 2 diabetes (T2D).
- AstraZeneca's Farxiga Granted Breakthrough Therapy Designation In U.S. For Chronic Kidney Diseaseon October 1, 2020 at 11:53 pm
(AZN.L, AZN) said Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the company's Farxiga or dapagliflozin for patients with chronic kidney disease or ...
via Bing News